Market accessOfficial

Commission publishes joint clinical assessment report on camizestrant for breast cancer

🇪🇺 European Commission (DG SANTE) · Fri 06 Nov 2026

The report on camizestrant (Etcamah), assessed by Austria and Belgium under the EU HTA Regulation, was endorsed by Member States on 19 August 2026.

The European Commission has published a joint clinical assessment (JCA) report on camizestrant, marketed as Etcamah, a medicine for the treatment of breast cancer. The report was released on 6 November 2026 through the DG SANTE newsletter.

The assessment was carried out by the competent authorities of Austria and Belgium under the EU Health Technology Assessment (HTA) Regulation. Member States endorsed the report on 19 August 2026, and the Commission had granted marketing authorisation for the product on 20 July 2026.

According to the Commission, JCAs let Member States work together to assess the clinical benefits of new medicines and certain medical devices against existing health technologies. Patients and clinical experts are systematically consulted during the process, which produces a JCA report and a summary report. Member States will use these in their national decision-making procedures.

The Commission said further JCA reports will appear on its HTA website in the coming months. A JCA tracker table, updated regularly, lists the assessments under way. The newsletter item does not describe the report's findings, which are set out in the full document on the HTA website.

What it means for your team

  • Market-access teams should read the full camizestrant JCA report, as Member States will draw on it in national pricing and reimbursement procedures.
  • The timeline is a useful reference: authorisation on 20 July 2026, Member State endorsement on 19 August 2026 and publication on 6 November 2026.
  • Regulatory and HTA teams can follow the JCA tracker table to see which other assessments are ongoing and when reports may appear.

Official source: European Commission (DG SANTE) ↗

Article written by VigiEye from the official source (European Commission (DG SANTE)). AI-assisted; check the source before acting.

More Market access All →